In this study, we demonstrate novel GSE mediated anti-neoplastic mechanisms involving modulation of oncomir miR-106b, its molecular target p21, and correlated these findings to the in vivo efficacy of LP, against lung cancer. This evidence concerns the gene CDKN1A and lung cancer.